Observational study of amyloidosis and TTR gene carriers
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with amyloidosis, or you carry a mutation in the transthyretin gene (even if you have no symptoms).
- You were at least 18 years old when you were diagnosed.
- You agree to sign a consent form to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses PET/CT scans (specialized imaging) to look for early heart damage in people who carry a TTR gene mutation that can affect the heart. You may qualify if you carry this mutation, have heart failure, or are a healthy control, and have already participated in a related study at UT Southwestern.
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Hear when a new Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.